Rhythm Pharmaceuticals (RYTM) Reports In-Line Q1 EPS

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q1 EPS of ($2.35), in-line with the analyst estimate of ($2.35). Revenue for the quarter came in at $25.97 million versus the consensus estimate of $27.02 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• Cerebras CEO says investors misunderstood margin guidance
• GTA VI to catalyze a multi-year improvement in earnings power for TTWO, BTIG says
• JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’